Gossamer Bio Inc.   Report issue

For profit Phase 2 Phase 3
Founded: San Diego CA United States (2015)

Organization Overview

First Clinical Trial
2017
NCT03473236
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. | GB002, Inc. | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | GB004, Inc. | GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Gossamer Bio Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Seralutinib (5 trials)

Drugs in Phase 2 Trials (7)

fevipiprant (2 trials)

gb004 (2 trials)

gb1275 (1 trial)

gb5121 (1 trial)

gemcitabine (gemzar) (1 trial)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Asthma (Phase 2)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Familial Primary Pulmonary Hypertension (Phase 1)

Hypertension (Phase 2)

Nasal Polyps (Phase 2)

Polyps (Phase 2)

Sinusitis (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 8